BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35662120)

  • 1. Immunogenomics Parameters for Patient Stratification in Alzheimer's Disease.
    Huda TI; Diaz MJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
    J Alzheimers Dis; 2022; 88(2):619-629. PubMed ID: 35662120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas.
    Yeagley M; Chobrutskiy BI; Gozlan EC; Medikonda N; Patel DN; Falasiri S; Callahan BM; Huda T; Blanck G
    Pediatr Hematol Oncol; 2021 Apr; 38(3):251-264. PubMed ID: 33616477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.
    Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.
    Hudock TR; Barker VR; Manley BJ; Chobrutskiy A; Chobrutskiy BI; Diaz MJ; Song JJ; Blanck G
    Cancer Biomark; 2023; 38(1):103-110. PubMed ID: 37545223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrostatic Complementarities of Glioblastoma-Resident T-Cell Receptors and Cancer Testis Antigens Linked to Poor Outcomes and High Levels of Sphingosine Kinase-2 Expression.
    Arias MA; Cios KJ; Kacsoh DB; Montgomery BE; Song JJ; Patel AR; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy.
    Merlini M; Wanner D; Nitsch RM
    Acta Neuropathol; 2016 May; 131(5):737-52. PubMed ID: 26988843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members.
    Diaz MJ; Chobrutskiy BI; Zaman S; Blanck G
    Cancer Treat Res Commun; 2020; 24():100196. PubMed ID: 32769037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRB CDR3 chemical complementarity with HBV epitopes correlates with increased hepatocellular carcinoma, disease-free survival.
    Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
    J Med Virol; 2023 Aug; 95(8):e29043. PubMed ID: 37621059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer.
    Waweru JW; Mwangi KW; Barker VR; Gozlan EC; Yeagley M; Blanck G; Makokha FW
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4359-4366. PubMed ID: 36098856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting adaptive immune receptor recombination read recoveries from exome files to identify subsets of ALL and to establish TCR features that correlate with better outcomes.
    Gozlan EC; Chobrutskiy BI; Blanck G
    Int J Lab Hematol; 2022 Oct; 44(5):883-891. PubMed ID: 35527672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor resident, TRA anti-viral CDR3 chemical sequence motifs are associated with a better breast cancer outcome.
    Diaz MJ; Kacsoh DB; Patel DN; Yeagley M; Hsiang M; Blanck G
    Genes Immun; 2023 Apr; 24(2):92-98. PubMed ID: 36805542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma.
    Kacsoh DB; Diaz MJ; Gozlan EC; Sahoo A; Song JJ; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12047-12056. PubMed ID: 37421457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates.
    Hsiang M; Chobrutskiy BI; Diaz M; Huda TI; Creadore S; Zaman S; Cios KJ; Gozlan EC; Blanck G
    Transl Oncol; 2021 Jun; 14(6):101069. PubMed ID: 33780706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.
    Patel AR; Patel DN; Tu YN; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    J Biomol Struct Dyn; 2023 Jul; 41(10):4632-4640. PubMed ID: 35538689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.
    Kurbatskaya K; Phillips EC; Croft CL; Dentoni G; Hughes MM; Wade MA; Al-Sarraj S; Troakes C; O'Neill MJ; Perez-Nievas BG; Hanger DP; Noble W
    Acta Neuropathol Commun; 2016 Mar; 4():34. PubMed ID: 27036949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
    Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
    Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease.
    Mendonça CF; Kuras M; Nogueira FCS; Plá I; Hortobágyi T; Csiba L; Palkovits M; Renner É; Döme P; Marko-Varga G; Domont GB; Rezeli M
    Neurobiol Dis; 2019 Oct; 130():104509. PubMed ID: 31207390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of different tau sites during progression of Alzheimer's disease.
    Neddens J; Temmel M; Flunkert S; Kerschbaumer B; Hoeller C; Loeffler T; Niederkofler V; Daum G; Attems J; Hutter-Paier B
    Acta Neuropathol Commun; 2018 Jun; 6(1):52. PubMed ID: 29958544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Immune Hub Genes Associated With Braak Stages in Alzheimer's Disease and Their Correlation of Immune Infiltration.
    Qian XH; Liu XL; Chen SD; Tang HD
    Front Aging Neurosci; 2022; 14():887168. PubMed ID: 35619939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter
    Rullmann M; Brendel M; Schroeter ML; Saur D; Levin J; Perneczky RG; Tiepolt S; Patt M; Mueller A; Villemagne VL; Classen J; Stephens AW; Sabri O; Barthel H; On Behalf Of The German Imaging Initiative For Tauopathies Gii T
    Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.